Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alison Oliveto

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPsychiatry, College of Medicine
DivisionPSY Center for Addiction Research
Address441 Psychiatric Research Institute
4224 Shuffield Dr.
Mail Slot # 843
Little Rock AR 72205
Phone501-526-8441
vCardDownload vCard

    Collapse Research Funds 
    Collapse research activities
    UG1DA020024     (OLIVETO, ALISON)Jun 1, 2020 - Feb 28, 2025
    NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center - Dallas
    Clinical Trials Network: The Big South/West Node
    Role: Principal Investigator

    R01DA048948     (ADDICOTT, MERIDETH A)Aug 15, 2019 - May 31, 2024
    NIH/NIDA
    Distress Tolerance and Smoking Cessation
    Role: Co-Investigator

    UL1TR003107     (JAMES, LAURA P)Jul 1, 2019 - Jun 30, 2024
    NIH/NCATS
    Expanding Translational Research in Arkansas
    Role: Co-Investigator

    R21DA045246     (WRIGHT, PATRICIA B)Sep 30, 2018 - Aug 31, 2020
    NIH/NIDA
    Improving Treatment Strategies for Prescription Opioid Use Disorder- Resubmission
    Role: Co-Investigator

    U54TR001629     (JAMES, LAURA P)Sep 26, 2017 - Aug 31, 2018
    NIH/NCATS
    Expanding Translational Research in Arkansas
    Role: Co-Investigator

    R01DA039088     (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021
    NIH/Nat. Inst. on Drug Abuse
    Improving Treatment Outcomes for Prescription Opioid Dependence
    Role: Principal Investigator

    R21DA034824     (MANCINO, MICHAEL)Aug 1, 2013 - Jul 31, 2015
    NIH/Nat. Inst. on Drug Abuse
    Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
    Role: Co-Investigator

    R21DA035325     (OLIVETO, ALISON)Apr 15, 2013 - Mar 31, 2016
    NIH/Nat. Inst. on Drug Abuse
    Improving Buprenorphine Detoxification Outcomes with Isradipine
    Role: Principal Investigator

    R01AA016917     (OLIVETO, ALISON)Jun 5, 2012 - Jul 31, 2012
    NIH/Nat. Inst. on Alcohol Abuse & Alcoholism - Pass Through: Dartmouth College
    Family Bases Contingency Management for Adolescent Alcohol Abuse
    Role: Principal Investigator

    R21DA031837     (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015
    NIH/Nat. Inst. on Drug Abuse
    Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans
    Role: Principal Investigator

    R21DA029842     (OLIVETO, ALISON)Aug 1, 2011 - Jun 30, 2015
    NIH/Nat. Inst. on Drug Abuse
    Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
    Role: Principal Investigator

    R01DA026916     (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013
    NIH/Nat. Inst. on Drug Abuse
    Monoamine Antagonist Therapies for Methamphetamine Abuse
    Role: Co-Investigator

    P20RR020146     (GARCIA-RILL, EDGAR E.)Aug 29, 2009 - Sep 8, 2012
    NIH/NCRR
    Center for Translational Neuroscience
    Role: Co-Investigator

    R01DA014388     (OLIVETO, ALISON)Jul 9, 2001 - Jun 30, 2006
    NIH/Nat. Inst. on Drug Abuse
    Behavioral Effects of GHB in Healthy Volunteers
    Role: Principal Investigator

    R01DA013441     (OLIVETO, ALISON)Jul 1, 2000 - Dec 31, 2012
    NIH/Nat. Inst. on Drug Abuse
    Disulfiram for Cocaine Abuse in Methadone-Maintained Patients
    Role: Principal Investigator

    R01DA010017     (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012
    NIH/Nat. Inst. on Drug Abuse
    Opioid Antagonist Discrimination: A Model of Withdrawal
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Schneider A, Mullinax S, Hall N, Acheson A, Oliveto AH, Wilson MP. Intramuscular medication for treatment of agitation in the emergency department: A systematic review of controlled trials. Am J Emerg Med. 2020 Jul 09. PMID: 33071100.
      View in: PubMed
    2. Wilson MP, Cucciare MA, Porter A, Chalmers CE, Mullinax S, Mancino M, Oliveto AH. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids. Am J Emerg Med. 2020 03; 38(3):503-507. PMID: 31221474.
      View in: PubMed
    3. Chalmers CE, Mullinax S, Brennan J, Vilke GM, Oliveto AH, Wilson MP. Screening Tools Validated in the Outpatient Pain Management Setting Poorly Predict Opioid Misuse in the Emergency Department: A Pilot Study. J Emerg Med. 2019 Jun; 56(6):601-610. PMID: 31043338.
      View in: PubMed
    4. Nahata R, Mancino MJ, Thostenson J, Oliveto AH. Survey of Treatment Preferences for Opioid Use Disorder. Jacobs J Addict Ther. 2018; 5(3). PMID: 31131330.
      View in: PubMed
    5. Bashiri M, Mancino MJ, Stanick VA, Thostenson J, Kosten TR, Oliveto AH. Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict. 2017 Dec; 26(8):807-814. PMID: 29115703.
      View in: PubMed
    6. Bashiri M, Greenfield LJ, Oliveto A. Telemedicine Interest for Routine Follow-Up Care Among Neurology Patients in Arkansas. Telemed J E Health. 2016 06; 22(6):514-8. PMID: 26684500.
      View in: PubMed
    7. Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014 Apr; 34(2):234-9. PMID: 24525654.
      View in: PubMed
    8. Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302. PMID: 23855333.
      View in: PubMed
    9. Atkinson TS, Sanders N, Mancino M, Oliveto A. Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. J Addict Med. 2013 Jul-Aug; 7(4):243-8. PMID: 23648640.
      View in: PubMed
    10. Oliveto A, Mancino M, Sanders N, Cargile C, Benjamin Guise J, Bickel W, Brooks Gentry W. Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. Eur J Pharmacol. 2013 Sep 05; 715(1-3):424-35. PMID: 23524089.
      View in: PubMed
    11. Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41. PMID: 21707811.
      View in: PubMed
    12. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011 Mar; 37(2):131-6. PMID: 21219261.
      View in: PubMed
    13. Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011 Jan 15; 113(2-3):184-91. PMID: 20828943.
      View in: PubMed
    14. Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010 Jul; 21(4):332-42. PMID: 20526195.
      View in: PubMed
    15. Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr; 19(2):169-77. PMID: 20163389.
      View in: PubMed
    16. Oliveto A, Pruzinsky R, Poling J, Gentry WB, Martell B, Gonsai K, Kosten TR. Behavioral effects of GHB in humans. Behavioural Pharmacology. 2010; 21(4):332-42.
    17. McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, Oliveto A. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol. 2009 Oct; 29(5):488-91. PMID: 19745650.
      View in: PubMed
    18. Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis. Pharmacol Biochem Behav. 2008 Oct; 90(4):787-96. PMID: 18585405.
      View in: PubMed
    19. Chopra M.P, Feldman Z.L, Mancino M.J, Oliveto A. Response to naloxone versus placebo in opioid-dependent humans responding under a naloxone discrimination procedure: influences of sex and opioid maintenance dose. Pharmacology, Biochemistry and Behavior. 2008; 90(4):787-96.
    20. Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol. 2007 Oct; 15(5):453-60. PMID: 17924779.
      View in: PubMed
    21. Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007 May-Jun; 16(3):187-94. PMID: 17612822.
      View in: PubMed
    22. González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007 Feb 23; 87(1):1-9. PMID: 16930857.
      View in: PubMed
    23. Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE. Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology. 2006 Mar; 31(3):644-50. PMID: 16123763.
      View in: PubMed
    24. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb; 63(2):219-28. PMID: 16461866.
      View in: PubMed
    25. Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend. 2005 Aug 01; 79(2):157-65. PMID: 16002025.
      View in: PubMed
    26. Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17. PMID: 15804873.
      View in: PubMed
    27. Hughes JR, Oliveto AH, Riggs R, Kenny M, Liguori A, Pillitteri JL, MacLaughlin MA. Concordance of different measures of nicotine dependence: two pilot studies. Addict Behav. 2004 Nov; 29(8):1527-39. PMID: 15451122.
      View in: PubMed
    28. Oliveto A, Poling J, Kosten TR, Gonsai K. Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. Eur J Pharmacol. 2004 May 03; 491(2-3):157-68. PMID: 15140632.
      View in: PubMed
    29. Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004 Apr; 5(4):713-25. PMID: 15102558.
      View in: PubMed
    30. Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004 Mar-Apr; 13(2):191-201. PMID: 15204669.
      View in: PubMed
    31. Kosten T.R, Falcioni J, Oliveto A, Feingold A. Depression predicts poor treatment response with desipramine and methadone or buprenorphine among cocaine and opioid dependent patients. American Journal on the Addictions. 2004; 13(2):191-201.
    32. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003 Nov; 98(11):1625-32. PMID: 14616189.
      View in: PubMed
    33. Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514. PMID: 14510037.
      View in: PubMed
    34. Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR. D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol. 2003 Aug; 11(3):237-46. PMID: 12940503.
      View in: PubMed
    35. Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav. 2003 Jul; 75(4):801-8. PMID: 12957222.
      View in: PubMed
    36. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003 Jun 05; 70(3):315-25. PMID: 12757969.
      View in: PubMed
    37. Kosten T, Poling J, Oliveto A. Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction. 2003 May; 98(5):665-71. PMID: 12751984.
      View in: PubMed
    38. Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend. 2002 Apr 01; 66(2):173-80. PMID: 11906804.
      View in: PubMed
    39. Feingold A, Oliveto A, Schottenfeld R, Kosten TR. Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict. 2002; 11(2):111-23. PMID: 12028741.
      View in: PubMed
    40. Gonzalez G, Oliveto A, Kosten TR. Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs. 2002; 62(9):1331-43. PMID: 12076182.
      View in: PubMed
    41. Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacol Biochem Behav. 2002 Jan-Feb; 71(1-2):85-96. PMID: 11812511.
      View in: PubMed
    42. Oliveto A.H, Rosen M, Kosten T.A, Hameedi F, Woods S, Kosten T.R. Naloxone discrimination in opioid-dependent humans under a novel-response discrimination procedure. Experimental and Clinical Psychopharmacology. 1998; (6):169-178.
    43. Oliveto A.H, Kosten T. R. New Treatments for Opiate Dependence. Buprenorphine. 1997.
    44. Hughes J.H, Oliveto A.H, Higgins S.T, Bickel W.K, Terry S.Y. Saying vs. doing and other methodological issues in the study of human drug self-administration. Experimental and Clinical Psychopharmacology. 1996; (4):234-238.
    45. Best S.E, Oliveto A.H, Kosten T.R. Opioid Addiction: Recent Advances in Detoxification and Maintenance Therapy. CNS Drugs. 1996; (6):301-304.
    46. Kamien JB, Bickel WK, Oliveto AH, Higgins ST, Hughes JR, Richards AT, Badger GJ. Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: a retrospective analysis. Behav Pharmacol. 1995; 6(2):187 - 194.
    47. Hale K.L, Hughes J.R, Oliveto A.H, Higgins S.T. Caffeine self-administration and subjective effects in adolescents. Experimental and Clinical Psychopharmacology. 1995; (3):364-370.
    48. Hughes, J.R, Oliveto A.H, Bickel W.K, Higgins S.T, Badger G.J. The ability of low doses of caffeine to serve as reinforcers in humans: A replication. Experimental and Clinical Psychopharmacology. 1995; (3):1-6.
    49. Kamien JB, Bickel WK, Oliveto AH, Smith BJ, Higgins ST, Hughes JR, Badger GJ. Triazolam discrimination by humans under a novel response procedure: effects of buspirone and lorazepam. Behav Pharmacol. 1994; 5(3):315 - 325.
    50. Oliveto A.H, Kosten T.R, Schottenfeld R, Ziedonis D, Falcioni J. Cocaine use in buprenorphine- vs methadone-maintained cocaine users. American Journal of Addictions. 1994; (3):43-48.
    51. Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol. 1993; 4(3):237 - 246.
    52. McGaugh, J.D., Mancino, M., Gentry, W.B., Chopra, M., Cargile, C., Oliveto A. Open label modafinil for methamphetamine dependence: Safety and tolerability. 70th Annual Meeting of the College on Problems of Drug Dependence.
    53. Oliveto A, Feldman Z, Mancino, M.J. Alcohol dependence diagnosis influences response to disulfiram in dually cocaine- and opioid-dependent humans maintained on methadone. 70th Annual Meeting of the College on Problems of Drug Dependence.
    54. Mancino, M.J., Feldman, Z., Oliveto A. Gender differences in response to disulfiram treatment for cocaine dependence in methadone-stabilized opioid- and cocaine-dependent individuals. 70th Annual Meeting of the College on Problems of Drug Dependence.
    Oliveto's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _